Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Virpax Pharmaceuticals (VRPX)
NASDAQ:VRPX
RESEARCH TOOLSreports
Holding VRPX?
Track your performance easily
VRPX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $7.19
Previous Close$0.66
Volume41.22K
Average Volume (3M)197.38K
Market Cap
$5.35M
Enterprise Value$3.48M
Total Cash (Recent Filing)$1.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.82
Shares Outstanding4,887,581
10 Day Avg. Volume113,185
30 Day Avg. Volume197,378
Standard Deviation0.60
R-Squared0.00737
Alpha-0.00419
Financial Highlights & Ratios
Price to Book (P/B)-1.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Virpax Pharmaceuticals News
PremiumMarket News
3 Penny Stocks to Watch Now, 11/26/24
PremiumCompany Announcements
Virpax Pharmaceuticals Welcomes Jay Panis to Board
PremiumCompany Announcements
Virpax Pharmaceuticals Announces Board Member Resignation
PremiumCompany Announcements
Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations
PremiumCompany Announcements
Virpax Pharmaceuticals Announces New Chief Financial Officer
PremiumCompany Announcements
Virpax Pharmaceuticals Announces $5M Public OfferingBulls Say, Bears Say
Bulls Say
InnovationEnvelta is a novel analgesic with broad pain management potential.
Product DevelopmentVirpax has promising pre-clinical central nervous system (CNS) assets, primarily in pain management, with Probudur and Envelta.
Product PotentialProbudur could be a ~96 hour bupivacaine-based post-operative pain therapy.
Bears Say
Cash Flow And FundingCash on hand at quarter-end only provides sufficient funding through the end of 3Q24.
Financial StabilityVirpax did not consummate a ≥$5M financing with an institutional investor as previously agreed upon, increasing the risk that the financing cannot be completed.
Leadership StabilityVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
---
Ownership Overview
0.21%
Insiders
0.16% Mutual Funds
0.71% Other Institutional Investors
98.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRPX FAQ
What was Virpax Pharmaceuticals’s price range in the past 12 months?
Virpax Pharmaceuticals lowest stock price was $0.36 and its highest was $7.19 in the past 12 months.
What is Virpax Pharmaceuticals’s market cap?
Currently, no data Available
When is Virpax Pharmaceuticals’s upcoming earnings report date?
Virpax Pharmaceuticals’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were Virpax Pharmaceuticals’s earnings last quarter?
Virpax Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.431 earnings per share for the quarter, beating the consensus estimate of -$0.54 by $0.109.
Is Virpax Pharmaceuticals overvalued?
According to Wall Street analysts Virpax Pharmaceuticals’s price is currently Overvalued.
Does Virpax Pharmaceuticals pay dividends?
Virpax Pharmaceuticals does not currently pay dividends.
What is Virpax Pharmaceuticals’s EPS estimate?
Virpax Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virpax Pharmaceuticals have?
Virpax Pharmaceuticals has 8,087,581 shares outstanding.
What happened to Virpax Pharmaceuticals’s price movement after its last earnings report?
Virpax Pharmaceuticals reported an EPS of -$0.431 in its last earnings report, beating expectations of -$0.54. Following the earnings report the stock price went down -6.061%.
Which hedge fund is a major shareholder of Virpax Pharmaceuticals?
Currently, no hedge funds are holding shares in VRPX
---
Virpax Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.55%
12-Months-Change
Fundamentals
Return on Equity
-594.46%
Trailing 12-Months
Asset Growth
-97.67%
Trailing 12-Months
Company Description
Virpax Pharmaceuticals
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
---
VRPX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---